INT178209

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.39
First Reported 2004
Last Reported 2010
Negated 0
Speculated 2
Reported most in Body
Documents 7
Total Number 8
Disease Relevance 4.80
Pain Relevance 0.89

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
poly 2
B cells 2
brain 2
IFNA1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Kinase C 6 93.88 High High
cva 5 89.56 High High
Central nervous system 21 83.52 Quite High
cytokine 42 83.12 Quite High
Demyelination 5 81.60 Quite High
Multiple sclerosis 189 80.80 Quite High
imagery 33 73.64 Quite High
Inflammation 43 67.64 Quite High
Neuropeptide 7 50.00 Quite Low
chemokine 20 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Papillomavirus Infection 19 100.00 Very High Very High Very High
Hepatitis C Virus Infection 146 96.56 Very High Very High Very High
Infection 35 96.24 Very High Very High Very High
Recurrence 73 94.88 High High
Bronchiolo-alveolar Adenocarcinoma 1 92.68 High High
Wound Healing 2 92.20 High High
Death 30 89.88 High High
Cv General 3 Under Development 3 89.56 High High
Lung Cancer 4 89.00 High High
Hemorrhage 3 87.92 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The dose intensity of IFN was lower in patients with low CLcr (IFN plus placebo 92%; bevacizumab plus IFN 78%) and ?
Negative_regulation (lower) of IFN Binding (intensity) of
1) Confidence 0.39 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721410 Disease Relevance 0.44 Pain Relevance 0.04
In 1998, the FDA approved the combination of IFN-?
Negative_regulation (approved) of IFN Binding (combination) of
2) Confidence 0.29 Published 2010 Journal Hepatitis Research and Treatment Section Body Doc Link PMC2990099 Disease Relevance 0.94 Pain Relevance 0.03
In addition, E2 and CpG also increased the stimulatory capacity of PDCs to B cells, and the viability of B cells was decreased after neutralizing IFN-?
Negative_regulation (decreased) of IFN Binding (neutralizing) of in B cells
3) Confidence 0.12 Published 2009 Journal PLoS ONE Section Abstract Doc Link PMC2793013 Disease Relevance 0.15 Pain Relevance 0.04
1a) decreases the frequency of exacerbations, slows the progression of physical disability, and reduces the development of brain lesions.7 IFN?
Negative_regulation (reduces) of IFN Binding (development) of in brain
4) Confidence 0.10 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2938285 Disease Relevance 0.87 Pain Relevance 0.47
A recent study was conducted to determine whether combination daclizumab and IFN ?
Spec (whether) Negative_regulation (daclizumab) of IFN Spec (determine) Binding (determine) of
5) Confidence 0.09 Published 2010 Journal Drug Design, Development and Therapy Section Body Doc Link PMC2998807 Disease Relevance 0.88 Pain Relevance 0.17
Two weeks after the booster injection (at week 10 after the first injections), however, all six animals injected with antigen together with poly ICLC had developed HPV-specific, IFN-?
Negative_regulation (developed) of IFN Binding (specific) of in poly associated with papillomavirus infection
6) Confidence 0.05 Published 2009 Journal PLoS Pathogens Section Body Doc Link PMC2660151 Disease Relevance 0.26 Pain Relevance 0
DCwere matured with a combination of LPS, CD40L and IFN-?
Negative_regulation (matured) of IFN Binding (combination) of
7) Confidence 0.04 Published 2004 Journal J Transl Med Section Body Doc Link PMC441417 Disease Relevance 1.19 Pain Relevance 0.04
Studying the possible crosstalk between PACAP and IFN?
Spec (possible) Negative_regulation (possible) of IFN Binding (crosstalk) of
8) Confidence 0.03 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2885411 Disease Relevance 0.07 Pain Relevance 0.09

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox